PEG-aspargase and DEP regimen combination therapy for refractory Epstein–Barr virus-associated hemophagocytic lymphohistiocytosis

PEG-aspargase and DEP regimen combination therapy for refractory Epstein–Barr virus-associated hemophagocytic lymphohistiocytosis

Abstract Background Epstein–Barr virus-associated hemophagocytic lymphohistiocytosis (EBV-HLH) is the most frequent subtype of secondary HLH triggered by infections. Previous studies have shown that ~30 % or more of patients with EBV-HLH do not respond to standard therapy. This study investigated th...

Full description

Bibliographic Details
Main Authors: Jingshi Wang, Yini Wang, Lin Wu, Jia Zhang, Wenyuan Lai, Zhao Wang
Format: Article
Language:English
Published: BMC 2016-09-01
Series:Journal of Hematology & Oncology
Subjects:
PEG-aspargase
Epstein–Barr virus
Hemophagocytic lymphohistiocytosis
Online Access:http://link.springer.com/article/10.1186/s13045-016-0317-7

Internet

http://link.springer.com/article/10.1186/s13045-016-0317-7

Similar Items